A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07704892 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Dysfunction-associated Steatohepatitis

Interventions

DRUG: Efimosfermin alfa
DRUG: Placebo

Sponsor

GlaxoSmithKline